Psychiatr. praxi. 2021;22(1):17-24 | DOI: 10.36290/psy.2021.003

Addictions in Patients with Attention-Deficit/Hyperactivity Disorder

MUDr. Jela Hrnčiarová
Psychiatrická klinika, Fakultní nemocnice Hradec Králové

Attention-deficit/hyperactivity disorder (ADHD) in adults is clinicaly established by review of symptoms and impairment. ADHD in adults is associated with significant psychiatric comorbidity and higher than average rates of diviorce, unemployment, motor vehicle accidents and i tis a risk factor for substance abuses. ADHD is associated with different characteristic of substance abuse: substance abuse transitions more rapidly to dependence, and lasts longer in adults with ADHD than those without ADHD. Self-medication may be a factor in the high rate of substance abuse in adults with ADHD. Pharmacologic treatment includes noradrenergic agents and stimulants plays a fundamental role in the management of ADHD. It reduces the risk of substance abuse in patients with ADHD. Treatment include a combination od addiction treatment, psychotherapy and pharmacotherapy. Monitoring of patients during treatment is necessary to ensure compliance with the treatment plan.

Keywords: ADHD in adults, addiction, etiology, diagnosis, treatment, stimulants, atomoxetine.

Published: April 15, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrnčiarová J. Addictions in Patients with Attention-Deficit/Hyperactivity Disorder. Psychiatr. praxi. 2021;22(1):17-24. doi: 10.36290/psy.2021.003.
Download citation

References

  1. Biederman J. Attention‑deficit/hyperactivity disorder: a selective overview. Biological Psychiatry. 2005 1; 57(11): 1215-1220. Go to original source... Go to PubMed...
  2. Barkley R. Attention‑deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: Guilford Press, 3rd ed., 2005, 305 p.
  3. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Srrvey Replication. Am J Psychiatry. 2006; 163: 716-723. Go to original source... Go to PubMed...
  4. Wilens TE. Impact od ADHD and Its Treatment on Substance Abuse in Adults, Journal of Clinical Psychiatry, 2004, 65(Supl 3), 38-45. Go to PubMed...
  5. Blum K, Chen ALC, Braverman ER, Comings DE, Chen TJH, et al. Attention‑deficit‑hyperactivity disorder and reward deficiency syndrome, Neuropsychiatr Dis Treat 2008; 4(5): 893-918. Go to original source... Go to PubMed...
  6. Biederman J, Gao H, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of ADHD symptoms from two pacebo‑controlled stdies of atomoxetine in children. Biol Psychiatry 2006; 60: 1106-1110. Go to original source... Go to PubMed...
  7. Krause J, Dresel SH, Krause KH, et al. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev. 2003; 27: 605-615. Go to original source... Go to PubMed...
  8. Faraone SV. etiology and pathophysiology of adult ADHD. Primary Psych 2004; 11, 28-40.
  9. Masopust J, Mohr P, Anders M, Přikryl R. Diagnostika a farmakoterapie ADHD v dospělosti, Psychiatrie pro praxi 2014, 15(3): 112-117.
  10. Paclt I. Diagnostika hyperkinetického syndromu v dospělosti. Psychiatrie pro Praxi 2002/3; 115-117.
  11. Mariani JJ, Levin FJ. Treatment Strategies for. Co‑Occuring ADHD and Substance Use Disorders, American Journal od Addictions 2007; 16/Supl 1: 45-56. Go to original source... Go to PubMed...
  12. Breyer JL, et al. Youg adult gambling behaviors and their relationship with the persistence of ADHD, Gambl Stud 2009, 25(2): 227-238. Go to original source... Go to PubMed...
  13. Rubášová E, Kalina K, Miovský M, Čablová L, Šťastná L. Výskyt ADHD u osob závislých na ilegálních návykových látkách léčených v terapeutických komunitách v České republice - pilotní studie, česká Slovenská psychiatrie 2015, 11(5): 228-235.
  14. Miovský M, Čablová L, Kalina K, Šťastná L. Vliv ADHD na průběh a výsledek léčby závislostí u klientů terapeutických komunit: design výzkumného projektu, Adiktologie, 2014/14/4: 392-400.
  15. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE: Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug and Alcohol Dependence, 67/2, 2002: 149-156. Go to original source... Go to PubMed...
  16. Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of ADHD with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003, 111: 97-109. Go to original source... Go to PubMed...
  17. Hosák L, Hrdlička M, Libiger J, Dudová I a kol. Psychiatrie a pedopsychiatrie, Karolinum 2015: 368.
  18. Kalina K a kol. Klinická adiktologie, Grada, 2015: 225.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.